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Miniaturized shake-flask HPLC method for determination 
of distribution coefficient of drugs used in inflammatory 
bowel diseases
A new method for determination of distribution coefficient 
of drugs azathioprine, 6-mercaptopurine and 6-thiogua-
nine and nutrient folic acid used in the treatment of inflam-
matory bowel disease based on a miniaturized shake-flask 
and HPLC/DAD was developed. Special attention was 
made to the most commonly reported problems in the mea-
surement of distribution coefficients using a shake-flask 
method such as mixing technique, speed and time, the tem-
perature of experiment, type of buffer and its pH as well as 
n-octanol/buffer phase ratio. The concentration of com-
pounds in the buffer is determined by HPLC directly from 
shake flasks or conventional 2-mL vials. The developed 
method was fully validated according to ICH guidelines. 
Furthermore, experimental data were successfully com-
pared with lipophilicity and human intestinal absorption 
calculated by the use of four different theoretical approach-
es. The method shows potential for high-throughput mea-
surements of a large number of compounds.
Keywords: distribution coefficient logarithm, shake-flask, 
HPLC, in silico, inflammatory bowel disease
Lipophilicity represents one of the most studied and most frequently used fundamental 
physicochemical property that affects compound solubility, determines its passive trans-
port through biological membranes, influences biodistribution, metabolism, elimination 
and toxicity. 
A large variety of procedures for lipophilicity determination were developed. These 
methods can be divided into two major groups, direct and indirect ones. In the direct 
methods, the shake-flask and stir-flask procedures are included, whereas various sepa ra tion 
methods represent the indirect ones. Because of its simplicity and clear relationship to the 
partitioning phenomenon, the traditional shake-flask technique is regarded as a benchmark 
method against which other methods are validated. It consists of partitioning of the analyte 
in n-octanol and water (buffer) mixture, and afterward measuring the concentration of the 
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analyte in each phase. The lipophilicity of the analyte is expressed throughout logarithm of 
partition coefficient, log P, or for ionizable analytes throughout logarithm of distribution 
coefficient at certain pH, log DpH. Shake-flask procedure is applicable for hydrophilic and 
lipophilic compounds, as well as neutral and charged analytes. On the other side, it is time 
and labor consuming, requires relatively large amounts of pure compounds, complete 
solubility of analyte must be attained and n-octanol-water emulsions can cause severe 
problems. Furthermore, the accurate measurements of the partition and distribution 
coefficients require the use of highly sensitive and precise analytical methods (1).
In order to avoid these inconveniences, modifications of shake-flask methods have been 
published. These investigations were focused on the improvement of shake-flask 
performance in terms of reproducibility and lowering manual work during sample 
preparation procedures and/or finding more sensitive and selective analytical methods than 
the most commonly used UV-Vis spectrophotometric technique. 
One of the major disadvantages of the shake-flask method is a long sample preparation 
procedure. Therefore, Wenlock and co-workers (2) have proposed a modified shake-flask 
procedure for simultaneous measurement of the distribution coefficients of a mixture of up 
to 10 compounds using high-performance liquid chromatography and tandem mass 
spectrometry (LC/MS/MS). During the determination of partition and distribution 
coefficients of a highly hydrophobic compound, the concentration of the compound in 
n-octanol phase is much higher than that in the water phase, making it difficult to separate 
water and n-octanol phases without the contamination of water phase. To resolve this 
problem, a new water plug aspiration/injection method was successfully applied for the 
determination of distribution coefficient of highly hydrophobic compounds (3). Afterwards, 
the same group of authors also introduced an automated liquid-handling system to increase 
the throughput of measurements (4). Finally, several reports have shown remarkable 
improvements in the automatization and increase of throughput by using 96-well plates 
(3–6). In drug development, low amounts of test compounds are available for preclinical 
studies, thus Andrés and co-workers (7) have designed a shake-flask procedure for the 
determination of distribution coefficient from low drug amounts.
Traditionally, lipophilicity measurements were performed using a UV-Vis 
spectrophotometer (8–10). This technique suffers from low sensitivity and is not easily 
converted to a high-throughput format. Over the past decade, a number of studies have been 
taken to improve this assay. Numerous literature reports have shown a prominent place of 
the HPLC technique (7, 11–13). In recent years, hyphenated techniques (LC/MS and LC/MS/
MS) have received ever-increasing attention due to superior selectivity and sensitivity of MS 
detector (2–5, 14). To improve the accuracy of the method, Nishimura and co-workers (6) have 
introduced the injection marker into a shake-flask procedure followed by LC/MS analysis. 
Other separation techniques, such as thin-layer chromatography (15), ultra-performance 
liquid chromatography (16) and capillary zone electrophoresis (17), have also been employed 
to achieve increased throughput, sensitivity, precision and accuracy of the determination of 
partition and distribution coefficients.
The term inflammatory bowel disease (IBD) describes two well-established, but not 
completely distinguished disease entities: ulcerative colitis and Crohn’s disease. These 
conditions comprise of immune-mediated inflammatory processes occurring in genetically 
predisposed individuals. It is presumed that the environmental triggers react with the 
intestinal flora, thus causing inflammation in the gastrointestinal tract (18), leading to 
diarrhea, abdominal pain and nutrient malabsorption among others (19). These conditions 
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are treated with a broad spectrum of drugs: corticosteroids and monoclonal antibodies, such 
as infliximab, are used for more severe cases, whereas aminosalicylate mesalazine with its 
prodrugs and purine analogues azathioprine (AZA), 6-mercaptopurine (6-MP) and 6-thio-
guanine (6-TG) are helpful in the maintenance of the remission. Patients are also often pre-
scribed folic acid (FA) for the treatment of megaloblastic anemia caused by the aforemen-
tioned malabsorption.
Fixed-dose combinations (FDC) improve patient adherence and should be considered 
in patients with chronic diseases (20), therefore a FDC of FA and one of the purine analogues 
could be useful in the treatment of IBD. Prior to the development of novel FDC, a complete 
insight into physicochemical properties of active pharmaceutical ingredients (API), one of 
which is lipophilicity, is needed in order to evaluate the interactions of drugs with each 
other, as well as with the human organism (21). To best of our knowledge, the lipophilicity 
of these compounds was investigated using indirect chromatographic techniques such as 
thin-layer chromatography (22, 23), as well as using the traditional shake-flask procedure 
with UV-Vis spectroscopy (24, 25).
In the spirit of above considerations, the purpose of this work was to optimize a minia-
turized shake-flask high-performance liquid chromatography with diode-array detector 
(HPLC/DAD) method for the determination of distribution coefficients of AZA, 6-MP, 6-TG 
and FA (Fig. 1).
An attempt has been made to develop an automatic sampling method instead of a man-
ual separation of two phases to increase the throughput of measurements and to minimize 
the manual interventions. The aim of our work was to present and discuss each method 
optimization step and to validate the proposed method in order to improve the reproduc-
ibility and accuracy of the measurements. A further purpose of this study was to assess the 
comparability of the experimental and theoretical results as well as to relate the experi-
mental log D7.4 values with pharmacokinetic parameters, specifically human intestinal 
absorption (HIA) of investigated compounds.
Fig. 1. Structures of investigated compounds: AZA (1), 6-MP (2), 6-TG (3) and FA (4).
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AZA, 6-MP, 6-TG, FA, dimethylsulfoxide and phosphate buffered saline (PBS) tablets, 
all HPLC grade, were obtained from Sigma Aldrich (Germany). Acetonitrile, HPLC grade, 
was obtained from J. T. Baker (Deventer, The Netherlands). Formic acid, HPLC grade, was 
purchased from Merck (Germany). n-octanol, purified, was obtained from VWR (France). 
Ultrapure water was prepared with a Mili-Q water purification system (Millipore, USA).
Methods
Shake-flask determination
Distribution coefficients were determined using pre-saturated solutions of n-octanol 
and 10 mmol L–1 PBS, pH 7.4. To achieve the saturation of PBS with n-octanol and vice versa, 
solvents were mixed as 1:1, stored for 24 h in an orbital shaker-incubator ES-20/60 (Biosan, 
Latvia) at 100 oscillations per min at 25.0 ± 0.1 °C. The prepared mixture was left overnight 
for phase segregation in the thermostat at 25.0 ± 0.1 °C.
Stock solutions of AZA, 6-MP and 6-TG were prepared using PBS pre-saturated with 
n-octanol in the concentration of 20 µg mL–1. A stock solution of FA was prepared using di-
methylsulfoxide in the concentration of 2000 µg mL–1. Working solutions were prepared 
daily by dilution of the stock solutions with PBS pre-saturated with n-octanol.
0.15 mL of working solution was added to 1.5 mL of n-octanol pre-saturated with PBS in 
amber 2-mL HPLC vials. The samples were then mixed in the mechanical shaker at 200 
 oscillations per min for 1 h at 25.0 ± 0.1 °C. Afterward, the samples were centrifuged using a 
Z 326 K table top centrifuge (HERMLE Labortechnik, Germany) for 30 min at 4000 g and 25 
°C to remove possible emulsions. The sample analyses were performed using the liquid chro-
matographic system Agilent 1100 (Agilent Technologies, Germany) and the chromatographic 
column ZORBAX SB-C8, dimensions 150 × 4.6 mm, particle size 5 µm with a suitable guard 
column ZORBAX SB-C8, dimensions 12.5 × 4.6 mm, particle size 5 µm both purchased from 
Agilent Technologies. The elution was carried out using ultrapure water with 0.1 % (V/V) 
formic acid as a mobile phase A and acetonitrile with 0.1 % (V/V) formic acid as a mobile phase 
B with a gradient program, starting with 5 % of the mobile phase B, ramping up linearly to 20 
% until 3 min, and once again ramping up linearly to 55 % until 7 min. Additional 3 minutes 
were needed to re-equilibrate the column. Both mobile phases were filtered through a mem-
brane filter, no. 66, diameter 47 mm, pore size 0.45 µm (Supelco, USA). The column tempera-
ture was set to 25.0 ± 0.1 °C and the flow rate of 1.0 mL min-1. The vials were placed in a rack 
on the autosampler at 25 °C. The injection volume was 10 µL, with a needle offset of 0.5 mm. 
The absorbance of the analytes during a chromatographic run was collected in the spectral 
range of 200–400 nm. The detection wavelength was the one providing the maximum peak 
height, that is, 280 nm for FA and AZA, 320 nm for 6-MP and 343 nm for 6-TG. The sample 
from the lower buffer phase was injected for HPLC analysis before and after equilibration 
with the n-octanol phase. All measurements were done in duplicate.
The log D7.4 values were calculated via equation 1:
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 (1)
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where c0PBS and cPBS were concentrations of the analyte in the buffer phase prior to and post 
equilibration and VPBS and Vn-octanol were the volumes of buffer and n-octanol phase, respec-
tively.
In silico prediction
Four online-available computer platforms for the evaluation of physicochemical and 
ADME parameters were used. List of predictors, lipophilicity indices and pharmacoki-
netic properties is given in Table I.
Table I. List of lipophilicity and pharmacokinetic property predictors
Program Parameter Abbreviation Website




Chemicalize distribution coefficient log DChemicalize www.chemicalize.com
pkCSM human intestinal absorption HIApkCSM www.biosig.unimelb.edu.au/pkcsm/





Statistical analysis was carried out using the statistical package Microsoft Office Excel 
2007 (Microsoft, Redmond, USA).
RESULTS AND DISCUSSION
Method development
Distribution coefficients obtained by the shake-flask method are strongly influenced 
by experimental conditions, thus optimization of experimental conditions was carefully 
performed. The optimization of the method was carried out using a univariate optimization 
approach. Different parameters influencing the distribution of analytes in n-octanol and 
buffer phases, including mixing technique, speed and time, the temperature of the 
experiment as well as phase ratio, were optimized with the one-variable-at-a-time method.
Several mixing techniques were investigated: vigorous shaking using a vortex and 
gentle mixing using a shaker and a stirrer. Vortex mixing was found to be the least time-
consuming. Still, both layers appeared cloudy even after leaving overnight. Therefore, 
gentle mixing was preferred to avoid emulsion formation. Visual inspection of post-mixing 
layers obtained by the shaker and the stirrer indicated clear layers of n-octanol and buffer. 
Another advantage of these sample preparation techniques is that the temperature of 
samples can be easily controlled. Both techniques gave reproducible data, still due to 
practical reasons for our laboratory, as the less manual intervention was needed, the 
mechanical shaker was chosen for further study.
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An important experimental parameter is shaking speed. Therefore, the partition of 
6-MP as a representative of purine analogues and FA was examined by varying shaking 
speed from 50 to 200 oscillations per minute. The obtained results have shown that the 
equilibration was not achieved at low shaking speeds, thus, 200 oscillations per minute 
were chosen for further experiments. To determine the optimum time required to shake 
the samples in order to reach the equilibrium, an experiment was conducted in which the 
sampling of the buffer phase for partition of 6-MP and FA was performed as a time-course. 
Therefore, the concentration of analytes in both phases was determined after 0.5, 1, 6 and 
12 h. Shaking time sufficient for the equilibration to be reached in HPLC vial was 1 h. 
Furthermore, it was important to evaluate the stability of analytes in the n-octanol/buffer 
mixtures. According to our findings, the compounds of interest were stable in the buffer 
phase for at least 1 h, as no peaks other than that of the main compound were observed.
It is well known that the distribution coefficients of compounds strongly depend on 
the temperature of the system (26). However, during the testing of the influence of the 
temperature on the distribution coefficients, it has been observed that FA was susceptible 
to thermal degradation, which is in agreement with the results of Delchier et al. (27). Ac-
cording to these findings, a temperature of 25 °C was chosen for further experiments. To 
minimize the influence of temperature all experiments were performed in well-controlled 
temperature conditions; samples were shaken in a thermostat at 25.0 ± 0.1 °C and were kept 
in HPLC autosampler at 25 °C until the analysis.
Regarding the buffer used for the procedure, PBS was chosen to mimic physiological 
conditions. Furthermore, UV transparency makes it ideal for HPLC analysis.
To obtain the satisfying reproducibility of the method, various phase ratios were test-
ed. Distribution coefficients were determined under different test conditions, whereby the 
ratios of buffer and n-octanol phase were varied: 10:1, 1:1 and 1:10. Best reproducibility of 
the results was obtained at 1:10 ratio, which was chosen for further experiments.
Fig. 2. Overlaid chromatograms of 6-TG (black), 6-MP (red), FA (blue) and AZA (green) with 
corresponding retention times (tR).
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Among different techniques available, HPLC has dominated the separation, identifi-
cation and quantitation of a broad spectrum of compounds in the last thirty years. Several 
stationary and mobile phases were used for the analysis of FA and purine analogues. Most 
of the chromatographic methods include the use of, almost exclusively, reversed-phase 
chromatographic columns C18 and C8, detectors such as UV-Vis or, if necessary, MS and 
mobile phases containing mixtures of polar organic solvent and acidified water (28–30). 
Therefore, the analysis of our samples was performed using a Zorbax SB-C8 column that 
can be used at low pH without degradation. To achieve a high-throughput analysis time 
of less than 7 min, gradient elution was used. The optimized conditions yielded sym-
metrical and sharp peaks of all the analytes without peak tailing (symmetry factors were 
above 0.8, theoretical plate count was more than 8477) (Fig. 2).
Validation of the method
As reported before (8, 9), the major disadvantage of the shake-flask method is 
unsatisfactory reproducibility and reliability of obtained partition and distribution 
coefficients. Thus, careful validation of the proposed method was performed to improve 
the quality and reproducibility of the obtained data. The method validation was performed 
following the recommendation of International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (31). The method was 
validated for selectivity, linearity, accuracy, sensitivity, precision, stability and robustness.
To evaluate the presence of potential interferences from the buffer phase, the sample 
to which no analyte had been added was evaluated. The obtained chromatogram reveals 
that no other components were co-eluted with compounds of interest (peak purity factors 
were higher than 999.7).
Linearity of the shake-flask method was estimated using five concentration levels for 
each analyte (0.5, 2.5, 10, 15 and 20 µg mL–1). The obtained correlation coefficients (r) were 
higher than 0.999 indicating excellent linearity of the method (Table II). Since small 
amounts of the lipophilic compounds were expected to be found in the buffer phase, 
sensitivity of the optimized method was one of the most important validation parameters. 
Limits of detection (LOD) and quantitation (LOQ) were determined on the basis of signal-
-to-noise ratios (S/N) of 3:1 and 10:1, respectively. As it can be seen from Table II, the meth-
od was proven to be quite sensitive for the determination of small concentrations of all 
analytes (LOQ ≤ 0.50 µg mL–1).
Precision and accuracy of the method were also evaluated. The analysis of the sam-
ples (10 µg mL–1) was repeated six times within the same day to determine repeatability 
Table II. Method calibration data







AZA 0.50–20 y = 31.60 x – 9.75 0.9995 0.14 0.46
6-MP 0.50–20 y = 68.20 x – 17.61 0.9997 0.07 0.23
6-TG 0.50–20 y = 72.21 x – 16.61 0.9998 0.13 0.42
FA 0.50–20 y = 25.47 x – 4.44 0.9999 0.15 0.50
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(intra-assay precision) and three times on two different days to determine intermediate 
precision (inter-assay precision) of the method. The obtained Relative Standard Deviation 
(RSD) values were lower than 0.71 % and 1.23 %, confirming high repeatability and inter-
mediate precision of the method (Table III). To determine the accuracy of the chromato-
graphic method, samples were analysed in triplicate on low (2.5 µg mL–1), medium (10 µg 
mL–1) and high (20 µg mL–1) concentration levels. All recoveries were in the range of 97.45 
to 100.76 %, confirming good accuracy of the method (Table III).
Robustness of the chromatographic method was also evaluated. Deliberate minor 
changes to the column temperature, gradient program and he mobile phase composition 
were made. RSD values of peak areas and retention times (tR) prior to and post changes 
were lower than 4.34 and 7.15 %, respectively.
As a part of the method validation, data were also generated to ensure that all ana-
lytes were stable at distinct timing and temperature conditions. Stability tests were per-
formed in terms of short-term (at room temperature for 8 hours) and long-term storage (in 
the refrigerator at –20 °C for 7 days) in standard solutions (10 µg mL–1). The percentage of 
analytes recovered from the samples ranged from 97.5 to 99.5 %. These results indicate that 
the degradation of all analytes was not significant during chosen conditions.
Determination of distribution coefficients
The optimized miniaturized shake-flask method was successfully applied for the deter-
mination of distribution coefficients of AZA, 6-MP, 6-TG and FA (Fig. 1). AZA, 6-MP and 6-TG 
belong to the group of thiopurines. They all share a purine skeleton, which is comprised of a 
pyrimidine ring fused to an imidazole ring, with a sulfur atom bonded at position C6, this 
also being the structure of 6-MP. 6-TG additionally has an amino group at position C2, where-
as AZA has 1-methyl-4-nitroimidazole ring bound to sulfur. FA, on the other hand, consists 
of three large sub-components: 2-amino-4-oxopteridine joined by a methylene bridge to p-
aminobenzoic acid, which is connected by an amide bond to l-glutamic acid.
The method was capable of measuring log D7.4 values from –3.65 to 0.08 (Table IV). 
Furthermore, RSD values lower than 0.89 % indicated high reproducibility of the method. 
As was expected, distribution coefficients were related to the chemical structure of the 
compound. AZA and 6-TG had very similar log D7.4 values; however, AZA appeared to be 
slightly more lipophilic, possibly due to the presence of the large imidazole derivative ring. 









recovery (%) ± RSD (%)
low medium high
AZA 0.71 0.82 100.22 ± 0.19 100.21 ± 0.71 99.84 ± 0.16
6-MP 0.58 0.91 99.91 ± 1.10 100.76 ± 0.75 99.32 ± 1.11
6-TG 0.41 0.38 99.34 ± 1.21 100.46 ± 0.66 99.15 ± 0.14
FA 0.57 1.23 97.45 ± 0.36 100.71 ± 0.54 99.84 ± 0.16
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Although 6-MP and 6-TG are very structurally similar, 6-MP appears to be more hydro-
philic, presumably due to a very small percentage of amino groups at position C2 of 6-TG 
being ionized at pH 7.4, thus increasing overall lipophilicity. The trend of increasing lipo-
philicity in the order of 6-MP < 6-TG < AZA is in accordance with results of Chrzanowska 
et al. (24, 32), whose experimentally measured partition coefficients at pH 7.4 followed the 
same order. Log D7.4 of FA is, however, significantly more negative than that of thiopurines, 
implying higher hydrophilicity. This could be due to the fact that FA contains a larger 
number of ionizable groups than the thiopurines, few of which are ionized at set pH, 
contributing to the overall negative charge of the molecule. Enyedy et al. (25) also came to 
similar conclusions regarding lipophilicity of FA while researching n-octanol-water 
distribution coefficient of FA and its derivatives by UV-Vis spectroscopy.  The insignificant 
difference of absorbance of aqueous solution of FA before and after equilibration was 
found (ΔAbs < 0.005 at λmax), implying very high hydrophilicity.
Comparison of experimental and predicted data
During the last several years, a number of calculation procedures were developed for 
rapid estimation of molecular lipophilicity (8, 9, 25). While many calculation procedures 
have been developed for rapid estimation of log P values, only several are available for 
prediction of distribution coefficient at various pH values. Experimentally obtained log 
D7.4 values were compared with the ones predicted by three calculation platforms: 
Chemicalize, PreADMET and ADMETlab (Table IV). Predicted log D7.4 values for 
Table IV. Experimental and predicted log D7.4 values for the investigated compounds and differences between 
experimental and predicted values for Chemicalize, PreADMET and ADMETLab platforms
Analyte
Experimental 
log D7.4 ± RSD 
(%)
Chemicalize PreADMET ADMETLab
log DChemicalize Δlog D7.4 log DPreADMET Δlog D7.4 log DLab Δlog D7.4
AZA 0.08 ± 0.55 1.15 1.07 0.67 0.59 0.11 0.03
6-MP –0.26 ± 0.09 –0.12 0.13 –0.47 0.22 –0.04 0.21
6-TG 0.06 ± 0.89 –0.35 0.41 –0.35 0.41 –0.09 0.15
FA –3.65 ± 0.30 –6.93 3.29 –0.59 3.05 –0.59 3.05
Table V. Human intestinal absorption data for all analytes predicted by pkCSM, ADMETLab and 
PreADMET platforms
Analyte HIApkCSM (%) HIALab (%) HIAPreADMET (%)
AZA 78.6 78.2 75.5
6-MP 91.0 81.3 87.8
6-TG 91.0 76.7 83.1
FA 2.3 39.8 23.2
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thiopurines for all of the platforms are somewhat in agreement with the experimental 
values, with ADMETLab platform showing the lowest difference between experimental 
and predicted values (Δlog D7.4 values were lower than 0.21). Predicted log D7.4 values for 
FA, on the other hand, ranged from –6.93 to –0.59, as compared to the experimental value 
of –3.65. As can be seen from the results, some platforms underestimate the lipophilicity 
of FA, while others overestimate it. This could be due to the fact that the platforms do not 
take the number of different ionizable groups, as well as the overall charge of such 
molecule, into account. These results may imply that more insight is needed in predicting 
lipophilicity parameters for more complex molecules.
HIA has often been connected to the lipophilicity of xenobiotics (33), therefore the 
selected parameter was predicted by pkCSM, PreADMET and ADMETLab platforms 
(Table V). According to obtained data, thiopurines are likely to be easily absorbed through 
the gastrointestinal tract, with predicted HIA percentages ranging from 75.5 to 91.0 %, 
while all of the platforms predicted poorer absorptions for FA (2.3 to 39.8 %). Seeing that 
pH in the small intestine is relatively neutral and thus close to 7.4 (34), these results can be 
correlated with the experimentally obtained log D7.4 values. The highly hydrophilic FA is 
less likely to pass the intestinal membrane by passive transport, thus having lower HIA 
percentages, unlike the more lipophilic thiopurines. A number of studies, however, 
determined the absorption of FA to be relatively high, ranging from 75 to 90 % (35). It can 
be concluded that the platforms predict HIA according to lipophilicity, but do not take the 
vital role of various transporters present in the human intestines into account. This 
approach consequently lowers the prediction accuracy. HIA is a very complex process and 
it seems that in silico predictions still have a long way to go in establishing such algorithms.
CONCLUSIONS
The miniaturized shake-flask followed by HPLC/DAD method for the determination 
of distribution coefficients of drugs and nutrient used in therapy of inflammatory bowel 
disease has been developed. Sample preparation has been simplified and accelerated 
through the use of conventional HPLC 2-mL vials as a flask. The obtained experimental 
log D7.4 values were compared with theoretical data obtained by 4 commercially available 
or free on-line physicochemical and pharmacokinetic property predictors. The 
miniaturized shake-flask procedure followed by HPLC/DAD analysis has proven to be 
fast, effective and, once optimized and validated, shows potential for high-throughput 
measurements of a large number of compounds. The obtained results may be useful for all 
researchers involved in the field of the determination of molecular lipophilicity.
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